Silo Pharma Finalizes Sublicense Deal for its Targeted Psilocybin Cancer Therapeutic Technology (SILO)
Agreement to explore the use of Silo Pharma’s Novel Peptide Englewood Cliffs, NJ, April 07, 2021 (GLOBE NEWSWIRE) — Silo
Read moreAgreement to explore the use of Silo Pharma’s Novel Peptide Englewood Cliffs, NJ, April 07, 2021 (GLOBE NEWSWIRE) — Silo
Read moreSilo Pharma could Utilize Data for Psilocybin Delivery potential to Central Nervous System Englewood Cliffs, NJ, Jan. 13, 2021 (GLOBE
Read moreEnglewood Cliffs, NJ, Jan. 11, 2021 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (OTCQB: SILO) a developmental stage biopharmaceutical company focused on
Read moreEnglewood Cliffs, NJ, Jan. 06, 2021 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (OTCQB: SILO) a developmental stage biopharmaceutical company focused on
Read more